Across TCGA pan-cancer cohorts, H2BC18 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated H2BC18 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher H2BC18 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated H2BC18 expression acts as an unfavorable survival marker.

SCLC, COAD, and SKCM are the cancer types where H2BC18 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	DFS	Median	All	0.164	0.625	.018	12	view →
COAD	DFS	Median	All	0.413	0.692	.036	6	view →
SKCM	DFS	Median	All	0.265	0.730	.009	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: H2BC18 tumor-vs-normal RNA expression · all H2BC18 data types